Corvus Pharmaceuticals to Host Investor Meeting

Corvus Pharmaceuticals will host an investor and analyst meeting on May 14, 2026, to present data on its drug soquelitinib. The data, which will be presented at the Society for Investigative Dermatology (SID) Annual Meeting, pertains to a Phase 1 clinical trial for atopic dermatitis. The meeting aims to highlight key findings from the trial, including late-breaker data, offering insights into the drug's potential efficacy and safety profile for treating the condition.